Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia.
Roddam
Philippa L
PL
Allan
James M
JM
Rollinson
Sara
S
Smith
Alexandra G
AG
Willett
Eleanor V
EV
Swirsky
David
D
Roman
Eve
E
Morgan
Gareth J
GJ
D000208:Acute Disease; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology* / Q000378:metabolism; D011110:Polymorphism, Genetic; D011878:Radiotherapy / Q000009:adverse effects; D059005:Topoisomerase II Inhibitors
D018906:Antineoplastic Agents, Alkylating; D059005:Topoisomerase II Inhibitors; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019389:Cytochrome P-450 CYP2D6